Sign In
Buy MGTX
$12.52
+0.310 (+2.54%)
At Close: Jul 21, 2026
Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
03:00pm, Thursday, 20'th Nov 2025
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors for metabolic, inflammatory, fibrotic, and centr
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Lags Revenue Estimates
10:15am, Thursday, 13'th Nov 2025
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to a loss of $0.54 per share a year ago.
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
08:00am, Thursday, 13'th Nov 2025
LONDON and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced financial and operatio
MeiraGTx: Latest Eli Lilly Partnership Ignites Riboswitch Technology Potential
03:30pm, Wednesday, 12'th Nov 2025
MeiraGTx Holdings plc secures a transformative partnership with Eli Lilly, granting worldwide rights to its AAV-AIPL1 gene therapy for LCA4. MGTX receives $75 million upfront, up to $400 million in mi
Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
09:10am, Monday, 10'th Nov 2025
MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to its experimental gene therapy for a rare, inherited disorder that causes s
LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic coll
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:01am, Wednesday, 05'th Nov 2025
MeiraGTx (MGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last?
09:21am, Wednesday, 22'nd Oct 2025
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
08:00am, Tuesday, 07'th Oct 2025
LONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhib
MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital
03:48am, Thursday, 25'th Sep 2025
MeiraGTx is a clinical-stage gene therapy biotech with end-to-end GMP. Its late-stage assets include AAV-AIPL1, AAV-AQP1, and Bota-Vec. AAV-AQP1 is in pivotal Phase 2 trials under the FDA's RMAT desig
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates
10:11am, Thursday, 14'th Aug 2025
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.76 per share a year ago.
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
08:00am, Thursday, 14'th Aug 2025
- Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (RI
3 Promising Genomics Stocks to Keep an Eye On in 2025
09:06am, Friday, 27'th Jun 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
04:30pm, Tuesday, 13'th May 2025
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's Technology Platforms for Gene and Cell Therapy Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx's T
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
10:15am, Tuesday, 13'th May 2025
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.77 per share a year ago.
